Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
RMD's MatrixCare sale sharpens its focus on sleep, breathing and connected care while freeing resources for AI-powered digital health.
RMD - ResMed Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$249.11
DETAILS
HIGH:
$276.00
LOW:
$225.00
MEDIAN:
$255.00
CONSENSUS:
$249.11
UPSIDE:
22.19%
Stock News
ResMed Analyst Backs Portfolio Reset
ResMed Inc. (NYSE:RMD) agreed to sell its MatrixCare business on Tuesday to Frazier Healthcare Partners, a private equity firm focused exclusively on health care, for $490 million.
Why ResMed (RMD) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top 50 High-Quality Dividend Growth Stocks For July 2026
I track a curated universe of 50 high-quality dividend growth stocks to identify opportune entry points based on valuation and future return potential. Year-to-date through June, the investable universe returned 8.69%, trailing SPY (10.10%) and SCHD (17.50%), but several individual stocks outperformed significantly. Currently, 39 out of 50 stocks offer a forward return estimate of at least 10%, with 22 appearing potentially undervalued by my free cash flow model.
ResMed to sell software business MatrixCare for $490 million
ResMed said on Tuesday it would sell its software business MatrixCare to private equity firm Frazier Healthcare Partners for $490 million in cash, as the health technology company sharpens its focus on sleep, breathing and home-based care.
Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare
SEATTLE--(BUSINESS WIRE)--Frazier Healthcare Partners ("Frazier"), a private equity firm focused exclusively on the healthcare industry, today announced it has entered into a definitive agreement to acquire MatrixCare (the “Company”) from Resmed (NYSE & ASX: RMD).MatrixCare is a leading provider of cloud-based EHR software purpose-built for out-of-hospital care settings, including skilled nursing, senior living, home health, hospice, and life plan communities. A multi-year winner of the Best.
Resmed Announces Agreement to Sell MatrixCare Business
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has entered into a definitive agreement to sell its MatrixCare business to Frazier Healthcare Partners, a private equity firm focused exclusively on health care. This move reflects Resmed's 2030 strategy by focusing on high-growth, scalable opportunities in sleep health, breathing health and connected home-based healthcare.
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
ResMed (RMD) Soars 4.2%: Is Further Upside Left in the Stock?
ResMed (RMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Here's Why ResMed (RMD) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
ResMed (RMD) Upgraded to Buy: Here's Why
ResMed (RMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think ResMed (RMD) Could Surge 28.21%: Read This Before Placing a Bet
The mean of analysts' price targets for ResMed (RMD) points to a 28.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2026 on Thursday, August 6, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results.
ResMed: Fear-Driven Selloff Creates A Compelling Margin Of Safety Entry Point
ResMed (RMD) exemplifies the razor-and-blade model, leveraging inevitability, brand loyalty, inexpensive recurring costs, and a superior user experience. RMD dominates the sleep apnea market with a 62% share in a vast, under-penetrated addressable market with huge future growth potential. RMD's financials are resilient, with consistent sales and earnings growth, no earnings misses in more than a decade, and a predictable business model.
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Here Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More
Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX) or SpaceX IPO rush is starting to fade somewhat.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed: GLP-1 Threats Are Overstated
My contrarian take on ResMed is that GLP-1 concerns are overstated, and even though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Other business threats come from PHG's reentrance and Apnimed's drug commercialization. While not to be overlooked, I still see RMD retaining its market dominance. The stock currently trades as if revenues are already declining and margins are contracting. But the opposite is true. Margins far exceed peers, and the top line grows at double digits.
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD gains from acquisition-led Residential Care Software growth, mask innovation and strong finances but faces macro and competitive pressures.
Top 50 High-Quality Dividend Growth Stocks For June 2026
I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD, but select names like LRCX (+343%) and KLAC (+208%) have dramatically outperformed since inception. Currently, 40 stocks offer forward return estimates of at least 10%, with 24 appearing potentially undervalued by my free cash flow model.
Price Targets
ResMed price target lowered to $225 from $240 at Jefferies
$225.00
(was $204.50)
Jefferies
ResMed price target lowered to $276 from $321 at RBC Capital
$276.00
(was $219.75)
RBC Capital
ResMed price target lowered to $225 from $227 at Wells Fargo
$225.00
(was $219.75)
Wells Fargo
ResMed price target lowered to $266 from $290 at KeyBanc
$266.00
(was $188.63)
KeyBanc
Morgan Stanley Downgrades ResMed (RMD) to Equalweight
$230.00
(was $193.94)
David Bailey
·
Morgan Stanley
ResMed price target lowered to $225 from $254 at Baird
$225.00
(was $203.87)
Robert W. Baird
ResMed price target lowered to $290 from $302 at KeyBanc
$290.00
(was $219.85)
KeyBanc
ResMed price target lowered to $255 from $300 at Evercore ISI
$255.00
(was $228.33)
Anthony Petrone
·
Evercore ISI
ResMed price target raised to $314 from $311 at RBC Capital
$314.00
(was $254.08)
Craig Wong-Pan
·
RBC Capital
ResMed price target raised to $265 from $260 at Stifel
$265.00
(was $257.61)
Stifel Nicolaus
ResMed price target raised to $302 from $299 at KeyBanc
$302.00
(was $257.61)
Brett Fishbin
·
KeyBanc
ResMed price target raised to $281 from $275 at Baird
$281.00
(was $257.61)
Robert W. Baird
ResMed price target raised to $275 from $270 at Piper Sandler
$275.00
(was $257.61)
Piper Sandler
ResMed (RMD) PT Lowered to $260 at Stifel
$260.00
(was $245.94)
Jonathan Block
·
Stifel Nicolaus
ResMed downgraded to Neutral from Outperform at Baird
$275.00
(was $253.07)
Robert W. Baird
ResMed (RMD) PT Raised to $345 at UBS
$345.00
(was $251.38)
Marcus Curley
·
UBS
ResMed price target lowered to $300 from $320 at Baird
$300.00
(was $246.88)
Robert W. Baird
ResMed price target raised to $299 from $298 at KeyBanc
$299.00
(was $244.12)
Brett Fishbin
·
KeyBanc
ResMed price target raised to $305 from $304 at Morgan Stanley
$305.00
(was $252.26)
David Bailey
·
Morgan Stanley
ResMed price target raised to $304 from $298 at Morgan Stanley
$304.00
(was $271.41)
Morgan Stanley